JP7565147B2 - 宿主細胞タンパク質の検出のための組成物及び方法 - Google Patents

宿主細胞タンパク質の検出のための組成物及び方法 Download PDF

Info

Publication number
JP7565147B2
JP7565147B2 JP2018553973A JP2018553973A JP7565147B2 JP 7565147 B2 JP7565147 B2 JP 7565147B2 JP 2018553973 A JP2018553973 A JP 2018553973A JP 2018553973 A JP2018553973 A JP 2018553973A JP 7565147 B2 JP7565147 B2 JP 7565147B2
Authority
JP
Japan
Prior art keywords
hcp
antibody
sample
recombinant polypeptide
cho
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018553973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516964A5 (enExample
JP2019516964A (ja
Inventor
マオ、グオジエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza AG
Original Assignee
Lonza AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza AG filed Critical Lonza AG
Publication of JP2019516964A publication Critical patent/JP2019516964A/ja
Publication of JP2019516964A5 publication Critical patent/JP2019516964A5/ja
Application granted granted Critical
Publication of JP7565147B2 publication Critical patent/JP7565147B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
JP2018553973A 2016-04-14 2017-04-12 宿主細胞タンパク質の検出のための組成物及び方法 Active JP7565147B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322621P 2016-04-14 2016-04-14
US62/322,621 2016-04-14
PCT/EP2017/058775 WO2017178526A1 (en) 2016-04-14 2017-04-12 Compositions and methods for the detection of host cell proteins

Publications (3)

Publication Number Publication Date
JP2019516964A JP2019516964A (ja) 2019-06-20
JP2019516964A5 JP2019516964A5 (enExample) 2020-04-23
JP7565147B2 true JP7565147B2 (ja) 2024-10-10

Family

ID=58645011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553973A Active JP7565147B2 (ja) 2016-04-14 2017-04-12 宿主細胞タンパク質の検出のための組成物及び方法

Country Status (14)

Country Link
US (3) US11353468B2 (enExample)
EP (2) EP3443348A1 (enExample)
JP (1) JP7565147B2 (enExample)
KR (1) KR102408260B1 (enExample)
CN (2) CN109564217A (enExample)
AU (1) AU2017251360A1 (enExample)
BR (1) BR112018071107A2 (enExample)
CA (1) CA3020808A1 (enExample)
EA (1) EA201892325A1 (enExample)
ES (1) ES2994760T3 (enExample)
IL (2) IL290358B2 (enExample)
MX (1) MX2018012550A (enExample)
SG (1) SG11201808992UA (enExample)
WO (1) WO2017178526A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL290358B2 (en) * 2016-04-14 2024-03-01 Lonza Ag Preparations and methods for detecting host cell proteins
US11268951B2 (en) * 2017-09-20 2022-03-08 Charles River Laboratories International, Inc. CHO host cell protein assay
CN109078628B (zh) * 2018-08-27 2021-06-11 西北大学 一种以苄胺为配基的高效疏水相互作用色谱介质、制备方法及其在蛋白质复性与纯化的应用
CN111665364B (zh) * 2019-03-08 2025-01-21 湖州申科生物技术股份有限公司 一种评估hcp检测用多克隆抗体覆盖率的方法
KR20220107586A (ko) 2021-01-25 2022-08-02 금오공과대학교 산학협력단 전기신호를 이용한 세포수 검출장치 및 이를 이용한 검출방법
CN114966038A (zh) * 2022-04-13 2022-08-30 翌圣生物科技(上海)股份有限公司 精确定量检测生物医药制品中残留sp2/0宿主细胞蛋白的方法及ELISA检测试剂盒
WO2024084264A1 (en) * 2022-10-17 2024-04-25 HAJIAN TEHRANI, Behrooz Immunoassay for detecting host cell proteins of high five cells
CN115894677A (zh) * 2022-12-01 2023-04-04 湖州申科生物技术股份有限公司 一种提高hcp检测抗体覆盖率的抗体组合及其应用
CN117192107A (zh) * 2023-09-11 2023-12-08 福建基诺厚普生物科技有限公司 一种工艺特异性宿主细胞蛋白残留的检测方法及试剂盒
WO2025224621A1 (en) * 2024-04-26 2025-10-30 Waters Technologies Corporation Host cell protein detection using lateral flow devices
CN118465164B (zh) * 2024-05-10 2025-02-14 上海澳斯康生物制药有限公司 一种用于检测hcp抗体覆盖率的方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005071410A1 (en) 2004-01-13 2005-08-04 Tanox, Inc. Detecting and quantifying host cell proteins in recombinant protein products
JP2015533378A (ja) 2012-10-30 2015-11-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２段階接線流限外濾過を使用するポリペプチドの精製

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2046920B1 (enExample) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US6797522B1 (en) * 1994-01-13 2004-09-28 The Trustees Of Columbia University In The City Of New York Synthetic receptors
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO1999034220A2 (en) * 1997-12-31 1999-07-08 Genentech, Inc. Real-time monitoring of an analyte by chromatography using an on-line assay
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
CN1321753A (zh) * 2000-04-29 2001-11-14 上海博德基因开发有限公司 一种新的多肽——人b细胞蛋白酪氨酸激酶13和编码这种多肽的多核苷酸
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US20030091976A1 (en) * 2001-11-14 2003-05-15 Ciphergen Biosystems, Inc. Methods for monitoring polypeptide production and purification using surface enhanced laser desorption/ionization mass spectrometry
US20060205010A1 (en) * 2003-04-22 2006-09-14 Catherine Allioux Methods of host cell protein analysis
US8728828B2 (en) * 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
CN101571549B (zh) * 2008-04-30 2013-08-14 上海泽润生物科技有限公司 Vero细胞HCP检测试剂盒及其应用
TWI610936B (zh) * 2008-10-20 2018-01-11 艾伯維有限公司 使用蛋白質ａ親和性層析進行抗體之分離及純化
CN103439512B (zh) * 2013-07-30 2014-05-07 通化东宝药业股份有限公司 一种检测特异性重组人胰岛素大肠杆菌残留宿主蛋白的方法
SG10201802525QA (en) 2013-09-13 2018-04-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
CN103792366B (zh) * 2014-01-21 2015-09-23 内蒙古必威安泰生物科技有限公司 口蹄疫疫苗宿主细胞蛋白双抗夹心酶联免疫检测试剂盒及使用方法
CN105021824A (zh) * 2015-07-06 2015-11-04 上海优者生物科技有限公司 用于定量检测生物医药制品中残留cho宿主细胞蛋白的elisa试剂盒及其使用方法
IL290358B2 (en) 2016-04-14 2024-03-01 Lonza Ag Preparations and methods for detecting host cell proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005071410A1 (en) 2004-01-13 2005-08-04 Tanox, Inc. Detecting and quantifying host cell proteins in recombinant protein products
JP2015533378A (ja) 2012-10-30 2015-11-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２段階接線流限外濾過を使用するポリペプチドの精製

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｂｉｏｔｅｃｈｎｏｌｏｇｙ ａｎｄ Ｂｉｏｅｎｇｉｎｅｅｒｉｎｇ，２０１４年，Ｖｏｌ．１１１，Ｎｏ．１２，ｐｐ．２３６７－２３７９
ＵＳＰ ３９：Ｔｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｐｈａｒｍａｃｏｐｅｉａ；ＮＦ ３４：Ｔｈｅ Ｎａｔｉｏｎａｌ Ｆｏｒｍｕｌａｒｙ：２０１６，ＵＳＰ ３９ Ｐｕｂｌｉｓｈｅｄ Ｇｅｎｅｒａｌ Ｃｈａｐｔｅｒ，＜１１３２＞Ｒｅｓｉｄｕａｌ Ｈｏｓｔ Ｃｅｌｌ Ｐｒｏｔｅｉｎ Ｍｅａｓｕｒｅｍｅｎｔ ｉｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｏｆｆｉｃｉａｌ：Ｍａｙ １，２０１６

Also Published As

Publication number Publication date
EA201892325A1 (ru) 2019-04-30
US11353468B2 (en) 2022-06-07
EP3443348A1 (en) 2019-02-20
CN115109148A (zh) 2022-09-27
KR102408260B1 (ko) 2022-06-10
MX2018012550A (es) 2019-07-08
CN109564217A (zh) 2019-04-02
EP3683579B1 (en) 2024-10-23
AU2017251360A1 (en) 2018-11-01
IL290358B2 (en) 2024-03-01
US12203948B2 (en) 2025-01-21
JP2019516964A (ja) 2019-06-20
EP3683579C0 (en) 2024-10-23
WO2017178526A1 (en) 2017-10-19
KR20180129927A (ko) 2018-12-05
US20220268792A1 (en) 2022-08-25
SG11201808992UA (en) 2018-11-29
US20220268791A1 (en) 2022-08-25
CA3020808A1 (en) 2017-10-19
BR112018071107A2 (pt) 2019-04-16
ES2994760T3 (en) 2025-01-30
IL290358A (en) 2022-04-01
EP3683579A1 (en) 2020-07-22
IL262297A (en) 2018-11-29
US20190128903A1 (en) 2019-05-02
IL290358B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
JP7565147B2 (ja) 宿主細胞タンパク質の検出のための組成物及び方法
US11372001B2 (en) Anti-human IgG4 monoclonal antibody and methods of making and using same
JP7707147B2 (ja) アルドステロン検出用抗体及びアルドステロンの免疫測定方法
JP2019532633A (ja) 診断用抗ｐｄ−ｌ１抗体およびその使用
KR102520342B1 (ko) 트롬빈 안티트롬빈 복합체의 측정 시약 및 측정 방법
CN104769433A (zh) 诊断或监测肾功能或者诊断肾功能异常的方法
AU2018294758B2 (en) Method for measuring serum amyloid A of various animals and reagent for measurement thereof
KR101658620B1 (ko) 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
US20250172568A1 (en) Afucosylation of hla-specific igg1 as a potential predictor of antibody pathogenicity in kidney transplantation
EP3760641A1 (en) Monoclonal antibody against apoa4, immunoassay method, and kit for measurement
EP4501958A1 (en) Hrg measuring method using anti-hrg monoclonal antibodies
JP4637856B2 (ja) 抗デクチン−１モノクローナル抗体を産生するハイブリドーマ
RU2779197C9 (ru) Способ определения аполипопротеина е4
RU2779197C2 (ru) Способ определения аполипопротеина е4
JP2011016773A (ja) 抗ポリヒスチジンタグ抗体及びそれを用いた非特異反応の回避方法
WO2026063525A1 (ja) ラテックス凝集法によるＶａｎｉｎ－１タンパク質の測定方法、測定試薬、及び測定キット
CN120209148A (zh) 检测ca19-9的抗体对、试剂和方法
WO2025068313A1 (en) A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
CN120005013A (zh) 一种抗c反应蛋白的抗体及其应用
CN121699014A (zh) 一种脑特异性蛋白产物9.5测定试剂盒
JP2024093998A (ja) 非特異反応を抑制可能な抗体溶液

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221220

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221221

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230210

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240724

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240930

R150 Certificate of patent or registration of utility model

Ref document number: 7565147

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150